Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Panel to vote on von Eschenbach

This article was originally published in The Gray Sheet

Executive Summary

Senate Health Education Labor & Pensions Committee schedules Sept. 20 vote on nomination of Andrew von Eschenbach to be permanent FDA commissioner despite the prospect of future holds. Sens. David Vitter (R-La.) and Jim DeMint (R-S.C.) have threatened to place holds on the nomination once it reaches the Senate floor due to the lack of a drug importation program and continued marketing of Danco Laboratories' abortion pill Mifeprex (mifepristone), respectively. Democratic Sens. Hillary Clinton (N.Y.) and Patty Murray (Wash.) only recently released their hold on the nominee following FDA's approval of Plan B for dual Rx/OTC status (1"The Gray Sheet" Aug. 28, 2006, In Brief)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023997

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel